| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5623773 | Alzheimer's & Dementia | 2016 | 11 Pages |
Abstract
CRFR1 antagonism presents a viable disease-modifying therapy for AD, recommending its advancement to early-phase human safety trials.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Cheng Zhang, Ching-Chang Kuo, Setareh H. Moghadam, Louise Monte, Shannon N. Campbell, Kenner C. Rice, Paul E. Sawchenko, Eliezer Masliah, Robert A. Rissman,